Cargando…

Antifibrotics in India

Detalles Bibliográficos
Autor principal:	Dhar, Raja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710963/ https://www.ncbi.nlm.nih.gov/pubmed/31464219 http://dx.doi.org/10.4103/lungindia.lungindia_379_19

Ejemplares similares

Commentary: Antifibrotic medications and wound healing after cardiac surgery
por: Balsam, Leora B.
Publicado: (2020)

The Elusive Antifibrotic Macrophage
por: Adhyatmika, Adhyatmika, et al.
Publicado: (2015)

Need for a universal thalassemia screening programme in India? A public health perspective
por: Thiyagarajan, Arulmani, et al.
Publicado: (2019)

Deciphering the Antifibrotic Property of Metformin
por: Septembre-Malaterre, Axelle, et al.
Publicado: (2022)

Guidance to physicians on managing asthma during the ongoing pandemic
por: Dhar, Raja, et al.
Publicado: (2021)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Antifibrotic Activity of Acylated and Unacylated Ghrelin
por: Angelino, Elia, et al.
Publicado: (2015)

Antifibrotic function of cGKI in the kidney
por: Schlossmann, Jens, et al.
Publicado: (2015)

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016)

Antifibrotic therapy to normalize the tumor microenvironment
por: Hauge, Anette, et al.
Publicado: (2020)

Antifibrotic Therapies: Will We Ever Get There?
por: Thompson, Alexander James, et al.
Publicado: (2010)

PPARG as therapeutic target for antifibrotic therapy
por: Ghallab, Ahmed, et al.
Publicado: (2020)

COPD Management during the COVID-19 pandemic
por: Salvi, Sundeep Santosh, et al.
Publicado: (2021)

Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group
por: Salvi, Sundeep Santosh, et al.
Publicado: (2022)

“Yap”-ing about the Antifibrotic Benefits of Prostacyclin
por: Huang, Steven K.
Publicado: (2019)

Dilated cardiomyopathy: antifibrotic effect of IGF1
Publicado: (2012)

Antifibrotic Effects of Roscovitine in Normal and Scleroderma Fibroblasts
por: Steinman, Richard A., et al.
Publicado: (2012)

Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015)

Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?
por: Chang, Yue, et al.
Publicado: (2020)

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020)

Antifibrotic drugs as therapeutic tools in resistant melanoma
por: Sanchez‐Laorden, Berta, et al.
Publicado: (2022)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

From Hair in India to Hair India
por: Trüeb, Ralph M
Publicado: (2017)

Economic burden of asthma in India
por: Koul, Parvaiz A, et al.
Publicado: (2018)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
por: Lyu, Xing, et al.
Publicado: (2019)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Antifibrotic activity a fermentation filtrate of Ganoderma lucidum
por: Kwon, Sang-Chul, et al.
Publicado: (2011)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail, Mona H, et al.
Publicado: (2011)

Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites
por: Miguel-Carrasco, José Luis, et al.
Publicado: (2017)

Adoption of Antifibrotic Medications: A Closer Look at the Data
por: White, Eric S., et al.
Publicado: (2021)

An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
por: Rupcic Rubin, Vinka, et al.
Publicado: (2021)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
por: Jangra, Anshika, et al.
Publicado: (2022)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
por: Li, Ji-Min, et al.
Publicado: (2023)

Commentary
por: Dhar, Rajat
Publicado: (2013)

Discovery and evaluation of inhibitor of LARP6 as specific antifibrotic compound
por: Stefanovic, Branko, et al.
Publicado: (2019)

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Li, Xiaohe, et al.
Publicado: (2019)

Antifibrotic effects of crocin on thioacetamide-induced liver fibrosis in mice
por: Algandaby, Mardi M.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rs2qkof3n61l5q7861auaf5lru